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Abstract
Background: The design of clinical research deserves special caution so as to safeguard the rights
of participating individuals. While the international community has agreed on ethical standards for
the design of research, these frameworks still remain open to interpretation, revision and debate.
Recently a breach in the consensus of how to apply these ethical standards to research in
developing countries has occurred, notably beginning with the 1994 placebo-controlled trials to
reduce maternal to child transmission of HIV-1 in Africa, Asia and the Caribbean. The design of
these trials sparked intense debate with the inclusion of a placebo-control group despite the
existence of a 'gold standard' and trial supporters grounded their justifications of the trial design
on the context of scarcity in resource-poor settings.
Discussion: These 'contextual' apologetics are arguably an ethical loophole inherent in current
bioethical methodology. However, this convenient appropriation of 'contextual' analysis simply fails
to acknowledge the underpinnings of feminist ethical analysis upon which it must stand. A more
rigorous analysis of the political, social, and economic structures pertaining to the global context
of developing countries reveals that the bioethical principles of beneficence and justice fail to be
met in this trial design.
Conclusion: Within this broader, and theoretically necessary, understanding of context, it
becomes impossible to justify an ethical double standard for research in developing countries.
Introduction
The design of clinical research trials deserves special cau-
tion, for such research is always at risk of crossing the fine
line between regard for individual rights and potential
exploitation of research subjects. Infamous experiments
like the Tuskagee Syphilis Study have rendered evident the
dangers for individuals when we cross that line. To safe-
guard human subjects, the international community has
agreed on standard ethical principles, particularly the
World Medical Association's Declaration of Helsinki;
while it is encouraging that these frameworks exist, they
remain open to interpretation, revision, and debate. With
the 1994 placebo-controlled trials to reduce maternal to
child transmission (MTCT) of HIV-1 initiated in Africa,
Asia, and the Caribbean, we saw a breach in our consensus
concerning the application of these principles, namely
how to apply ethical standards to research conducted in
the context of resource-poor settings.
In fact, the 'contextual' apologetics for this breach are
inherent, I will argue, in current bioethical methodology.
As an application of ethical theory, bioethics pays partic-
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ular attention to context by acknowledging the unique
influence of relationships and the immediate environ-
ment on an individual's experience. In terms of develop-
ing countries, bioethics has grounded its contextual
analysis on the discourse of scarcity and sacrifice [1]. In
particular, the use of placebo-controlled trials in develop-
ing countries has been justified by the contextual consid-
erations of scarcity – trials that would otherwise be
deemed unethical in developed countries. This conven-
ient appropriation of 'contextual' analysis simply fails to
acknowledge the underpinnings of feminist ethical analy-
sis upon which it must stand. A more rigorous considera-
tion of the political, social, and economic structures
pertaining to individual contexts must be sought, and we
must ensure that our international ethical standards are
scrutinized and applied at the appropriate level. Within
this broader, and theoretically necessary, understanding
of context, it becomes impossible to justify an ethical dou-
ble standard for research in developing countries.
Background: The debate over placebo-
controlled trials in developing countries
The debate over the application of research ethics in devel-
oping countries surfaced with the early prevention of
MTCT of HIV trials. While in 1994 there was an existing
protocol from the AIDS Clinical Trial Group 076 (ACTG
076) for preventing MTCT, high antiretroviral (ARV) costs
and insufficient infrastructure placed the regimen out of
reach for the majority of the HIV-infected population in
the developing world. To find a more cost-effective and
applicable treatment for resource-poor settings, rand-
omized placebo-controlled trials were initiated to investi-
gate a short-course ARV regimen. However, these studies
sparked intense debate as they clearly violated the condi-
tion of equipoise: that placebo groups are only deemed
ethical if there exists sufficient uncertainty regarding the
merit of the intervention. In other words, if there exists no
gold standard of care then placebos can be justified. The
arguments for not providing the 'gold standard' available
in developed countries were founded on the existing low
'standard of care' in the context of developing countries.
The NIH and CDC, both principal funding organizations
of the studies, defended the studies' design: "it is an unfor-
tunate fact that the current standard of perinatal care for
the HIV-infected pregnant women in the sites of the stud-
ies does not include any HIV prophylactic intervention at
all" and that placebo controls "will be the most reliable
answer to the question of the value of the study compared
to the local standard of care [2]." In opposition, Paul
Lurie, wrote to the United States Department of Human
Rights and Services: "unless you act now as many as 1002
newborn infants will die of unnecessary HIV infections
they will contract from...HIV-infected mothers in nine
unethical research experiments funded by your Depart-
ment [3]." Despite this early opposition, the trials began
in 16 countries and included over 12 000 HIV-infected
women [4].
Redefining the 'context' of developing countries
While traditional ethical theory seeks fundamental princi-
ples to guide our actions, much of the current bioethical
literature rejects claims to the effect that morality can be
reduced to a set of universal principles [5]. They argue that
the agent of moral decision (a patient, family member or
physician) is inextricably embedded in a complex web of
relationships. By accounting for the uniqueness of each
ethical situation, bioethics attempts to apply ethical the-
ory or principles relevantly to the context at hand. The
problem then becomes how to define context, for much of
our practical application of bioethics hinges on this point.
A specifically feminist bioethics also rejects the universal
claims of traditional ethical theory, but goes further to
place value on the political, economic, and social factors
that differentiate individual situations. In doing so, it pays
particular attention to power differentials that exist
between men and women, rich and poor, developed and
developing countries [6]. It is this broader scope of con-
text that must be applied to research standards in the
debate over the short-course ARV placebo-controlled tri-
als.
Applying the principles of bioethics at an 
appropriate level of analysis
Since the Belmont Report defined the four principles of
bioethics, namely the principles of non-maleficence,
beneficence, justice and autonomy, they have been used
to ensure that ethical standards are applied to research. To
begin, the principle of non-maleficence states that
research must cause no harm to subjects and the principle
of beneficence states that due to their participation in
research, all possible benefits to subjects should be maxi-
mized. This immediately raises some questions for the
case at hand. While it can be argued that no outright harm
was afforded to the mother-infant pairs in the placebo
group since their access to ARVs was no different than it
would have been within their country context, it raises the
question of to whose standard of care was the trial respon-
sible? Moreover, can we further justify using this low
standard of care within a resource-rich, developed world
led research trial, thus violating the principle of benefi-
cence? What is missing is an acknowledgement of the
interlocking political, social, and economic contextual
factors of these trials and an examination of what 'stand-
ard of care' ought to mean. Ultimately, the question
becomes whether the contextual argument is enough to
justify violating the principle of beneficence.
To answer this question, we must first make a distinction
between the accessibility of AZT within the developing
country as opposed to accessibility in a clinical trial. Sup-
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porters of the placebo-control design did not argue that it
was financially or logistically unfeasible to provide the
gold standard ACTG076 regimen for the control group,
but rather that it was unnecessary because of the low
standard of care which existed in the developing coun-
tries. Lurie and Wolfe argue that this contextualized
'standard of care' justifies withholding a readily available
treatment [7]. An individual's right to receive maximum
benefits from participating in research is thus determined
by their individual socio-economic status, and in turn,
their access to health care.
The tenuous nature of this contextualized justification
becomes clear when we take a broader view of the factors
determining an individual's access to health care. First, we
must acknowledge that a person's scope of choice is often
determined by forces beyond her own control. As Amartya
Sen describes, not only do those in developing countries
face economic deprivations, they are in turn subject to
substantial 'unfreedoms'. These 'unfreedoms' include lack
of employment (or freedom to participate in the market)
and lack of access to health care (or freedom to ward off
early mortality) [8]. In particular, access to health care is
often not determined entirely by individual choice, but
rather by the wealth of a country, its commitment to pop-
ulation health, and the distribution of its resources. When
one includes this understanding of the economic context
that dictates individual access to health care, context itself
seems like a grossly unfair justification for violating the
principle of beneficence. Here, the 'standard of care' argu-
ment only serves to exploit the individual, and take
advantage of her circumstance and poverty.
Furthermore, we can expand the scope of context to
include both an evaluation of a nation's internal health
care priorities and overriding global economic inequities.
Recognizing the role of developing nations in the global
economy, we see that it is not entirely by choice that
developing countries provide a standard level of care that
does not include adequate MTCT prophylaxis. Develop-
ing countries are in fact given very little option under the
continuing reverberations of the 1980s debt crisis. After
heavily borrowing from the International Monetary Fund
and the World Bank, countries have faced 'forced' eco-
nomic reform through the structural adjustment policies
of these lending institutions such as the devaluation of
currency and enforced transition into export-based econ-
omies. This economic re-structuring has either required or
caused a significant erosion of social service infrastructure,
including health care and has particularly impacted many
of the most vulnerable populations [9]. By dismissing the
international forces that define the range of economic
options available to developing countries, we isolate the
problems of the developing world and allow ourselves to
ignore our relative role and responsibility. Thus, within
this broader scope of context, developed nations leading
the research in question should recognize their intercon-
nected role in the determinants of global inequity and
should caution their support for the 'standard of care'
argument which only serves to reinforce such inequity.
When expanding the parameters of context, the use of pla-
cebo-controlled trials in developing countries also fails to
meet the principle of justice. This principle ensures that
those who bear the burden of research risk will ultimately
receive the benefits of the research [10]. In other words,
specific populations should never be targeted due to their
availability or compromised position. In the early debate
over the short-course AZT trials, Satcher and Varmus
argued that this principle was being satisfied since the tri-
als were specifically investigating cost effective treatments
for the HIV epidemic that was disproportionately affect-
ing the world's poorest nations [11]. This argument
hinges on a definition of context that isolates developing
countries as independently dealing with an overwhelming
epidemic and obscures our ability to apply the principle
of justice at an appropriate level of analysis.
To assess the principle of justice within a broader under-
standing of the HIV epidemic, we must determine
whether the research subjects would indeed receive ade-
quate benefits for their participation. At the beginning of
the debate, Annas and Grodin challenged the notion that
an affordable treatment would ever be operational given
the exceedingly low health care resources available to
developing countries [12]. While the feasibility of imple-
mentation may have been questionable in 1998, there has
been a global commitment to the prevention of MTCT
and some notable successes in reducing the rate of MTCT
with short course ARV regimens. Unfortunately, pro-
grammes designed for resource poor areas continue to fall
short of the overwhelming success seen in developed
countries where studies with highly active antiretroviral
therapy demonstrate transmission rates of 1% in a non-
breastfeeding population [13]. In contrast, the World
Health Organization estimates that in developing coun-
tries, only 1% to 35% of populations have access to pre-
ventative care, with the lowest coverage in countries most
significantly affected by the HIV epidemic [14]. Also, in
2002, it was estimated that 800 000 children acquired
HIV infections, the vast majority of which were in the
developing world [15]. While resource-rich populations
are virtually beating vertical transmission, developing
nations continue to struggle.
In terms of weighing the research subject's contributions
to the trials against their benefits, which ten years later
seems partial at best, an expanded context forces us to
look at all the potential beneficiaries of this research. It
has been argued that advances in more effective and
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cheaper methods of preventing vertical transmission are
as likely to be implemented in developed countries as in
developing countries [16]. The fact that these short-course
regimens have not become standard in the developed
world is due to their sub-standard reduction of transmis-
sion in comparison to more complex ARV regimens [17].
However, knowledge generated by these short-course tri-
als has been applied to other research. The promising
effects of short-course nevirapine trials in developing
countries prompted researchers to study whether adding
nevirapine to the more complex gold standard ARV regi-
men would further reduce transmission rates in the devel-
oped world [18]. This demonstrates that knowledge does
not stay within segregated developing-developed con-
texts. Isolating the HIV epidemic as a developing world
problem does not adequately acknowledge the global
scope of the disease nor the subsequent global benefit of
advances in treatment. Given the limited benefits to date
of MTCT programs and this larger web of beneficiaries, it
seems that while perhaps unintentional, the structure of
current research serves to exploit impoverished popula-
tions for the benefit of science and more developed
nations. In this context, the argument for the placebo-con-
trol trials violates the principle of justice.
Where does the debate stand now?
The 'standard of care' debate has continued since the
MTCT prevention trials and has prompted the inclusion
of paragraph 29 in the Declaration of Helsinki:
the benefits, risks, burdens, and effectiveness of a new
method should be tested against those of the best current
prophylactic, diagnostic, and therapeutic method. This
does not exclude the use of placebo, or no treatment, in
studies where no proven prophylactic diagnostic or thera-
peutic method exists [19].
This attempt to create more stringent standards for the use
of placebo-controlled trials regardless of the contextual
standard of care, has been attacked by the international
community as "out of touch with contemporary thinking"
[20] and overly constitutional [21]. In response to these
changes, there has been a flurry of independent interna-
tional organizations writing their own, opposing ethical
standards. Many, such as the Nuffield Council on Bioeth-
ics and the Council for International Organizations of
Medical Sciences, have come to the conclusion that there
should not be an absolute ruling on this matter, but that
study design can be qualified when all other standards are
satisfied and a sound scientific reason can be given for
using a placebo-control arm [22]. This is treading on dan-
gerous territory as the demands of science may outweigh
ethical safeguards for individuals. It seems the debate has
landed us back at the beginning with the Nuffield Coun-
cil's new guidelines:
Wherever appropriate, participants in the control group
should be offered a universal standard of care for the dis-
ease being studied. Where it is not appropriate to offer a
universal standard of care, the minimum standard of care
that should be offered to the control group is the best
intervention available for that disease as part of the
national public health system [23].
What determines the appropriateness of offering a univer-
sal standard of care may be scientific criteria or, as Schuk-
lenk argues, may be erroneously conflated with economic
criteria such as the low standard of care available in
resource-poor settings [24]. This dangerous return to jus-
tifying a double standard for research in developing coun-
tries shows us that instead of building a mature consensus
around the application of research ethics to developing
countries, the discourse has become even further
ensconced in the isolating and narrow context of the
developing world.
Conclusion
The arguments put forward to understand the ethical
dilemma created by the short-course ARV trials for the pre-
vention of MTCT of HIV should not be interpreted to
mean that research should never be done in developing
countries. Rather, developed nations need to honestly
assess their role in such research, take responsibility for
their actions, and abstain from the exploitation of ethical
loopholes as provided by the contextual nature of bioeth-
ics. It is essential that we consider context in our ethical
deliberations, but we must be critical of our definition of
context. It would be tragic if we allowed ethical principles
to be manipulated for the exploitation of vulnerable pop-
ulations, the psychological comfort of the true beneficiar-
ies, and the effacement of real differences between
individuals and populations. To this end, we must always
remember that the inclusion of context is a corrective to
traditional ethics, not an invitation to exploitation. As
demonstrated above, the framework of the short-course
ARV trials is fundamentally challenged when context is
taken seriously. However, the current global situation
does not engender optimism that this exploitative
research constitutes an isolated incident. We must not
shirk our own recognized ethical responsibilities – at the
heart of research design we must situate the proper articu-
lation of context, towards which I submit the above as a
first step.
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